Protective efficacy against serotype 1 rotavirus diarrhea by live oral rhesus–human reassortant rotavirus vaccines with human rotavirus VP7 serotype 1 or 2 specificity

Pediatric Infectious Disease Journal

Volumn 11, Issue 7, 1992, Pages 535-542

  Vesikari, Timo ^a   Ruuska, Tarja ^b   Green, Kim Y ^c   Flores, Jorge ^c   Kapikian, Albert Z ^c  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Rhesus human reassortant rota viruses; Rotavirus immunity; Rotavirus vaccine; Vaccine efficacy

Indexed keywords

ROTAVIRUS VACCINE;

ACTIVE IMMUNIZATION; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN ROTAVIRUS; IMMUNOGENICITY; INFANT; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SEROCONVERSION; SEROTYPE; VACCINATION; VACCINE PRODUCTION;

ADMINISTRATION, ORAL; ANIMAL; ANTIBODIES, VIRAL; CAPSID; DIARRHEA, INFANTILE; HUMAN; IMMUNOGLOBULIN A; INFANT; MACACA MULATTA; ROTAVIRUS; ROTAVIRUS INFECTIONS; SEROTYPING; SPECIES SPECIFICITY; SUPPORT, NON-U.S. GOV'T; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 0026724549     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/00006454-199207000-00006     Document Type: Article

References (23)

1. Edelman R. Perspective on the development and deployment of rotavirus vaccines. Pediatr Infect Dis J 1987;6:704-10.
2. Vesikari T. Clinical and immunological studies of rotavirus vaccines. Southeast Asian J Trop Med Publ Health 1988;19: 437-47.
3. Flores J, Perez-Schael I, Gonzalez M, et al. Protection against severe rotavirus diarrhea by rhesus rotavirus vaccine in Venezuelan infants. Lancet 1987;1:882-4.
4. Christy C, Madore HP, Pichichero ME, Gala C, Pincus P, Vosefski D, et al. Field trial of rhesus rotavirus vaccine in infants. Pediatr Infect Dis J 1988;7:645-50.
5. Gothefors L, Wadell G, Juto P, Taniguchi K, Kapikian AZ, Glass RI. Prolonged efficacy of rhesus rotavirus vaccine in Swedish children. J Infect Dis 1989;159:753-7.
6. Vesikari T, Rautanen T, Varis T, Beards GM, Kapikian AZ. Rhesus rotavirus candidate vaccine: clinical trial in children vaccinated between 2 and 5 months of age. Am J Dis Child 1990;144:285-9.
7. Rennels MB, Losonsky GA, Young AE, et al. An efficacy trial of the rhesus rotavirus vaccine in Maryland. Am J Dis Child 1990;144:601-60.
8. Chiba S, Yokoyama T, Nakata S, et al. Protective effect of naturally acquired homotypic and heterotypic rotavirus antibodies. Lancet 1986;2:417-21.
9. Midthun K, Greenberg HB, Hoshino Y, Kapikian AZ, Wyatt RG, Chanock RM. Reassortant rotaviruses as potential live rotavirus vaccine candidates. J Virol 1985;53:949-54.
10. Midthun K, Hoshino Y, Kapikian AZ, Chanock RM. Singlegene substitution rotavirus reassortants containing the major neutralization protein (VP7) of human rotavirus serotype 4. J Clin Microbiol 1986;24:822-6.
11. Perez-Schael L, Blanco M, Vilar M, et al. Clinical studies of a quadrivalent rotavirus vaccine in Venezuelan infants. J Clin Microbiol 1990;28:553-8.
12. Flores J, Perez-Schael J, Blanco M, et al. Comparison of reac- togenicity and antigenicity of M37 rotavirus vaccine and rhesus- rotavirus-based quadrivalent vaccine. Lancet 1990;2:330-4.
13. Vesikari T, Ruuska T, Delem A, Andre FE, Beards GM, Flewett TH. Efficacy of two doses of RIT 4237 bovine rotavirus vaccine for prevention of rotavirus diarrhoea. Acta Paediatr Scand 1991; 80:173-80.
14. Gouvea V, Ho MS, Glass R, et al. Serotypes and electrophero- types of human rotavirus in the USA: 1987-1989. J Infect Dis 1990;162:362-7.
15. Matson DO, Estes MK, Bums JW, Greenberg HB, Taniguchi K, Urasawa S. Serotype variation of human Group A rotaviruses in two regions of the USA. J Infect Dis 1990;162:605-14.
16. Ruuska T, Vesikari T. Rotavirus disease in Finnish children: use of numerical scores for clinical severity of diarrhoeal episodes. Scand J Infect Dis 1990;22:259-67.
17. Taniguchi K, Urasawa S, Morita HB, Greenberg HB, Urasawa S. Direct serotyping of human rotavirus in stools by an enzyme- linked immunosorbent assay using serotype 1-, 2-, 3- and 4- specific monoclonal antibodies to VP7. J Infect Dis 1987;155: 1159-66.
18. Losonsky GA, Rennels MB, Lim Y, Krall G, Kapikian AZ, Levine MM. Systemic and mucosal immune response to rhesus rotavirus vaccine MMU 18006. Pediatr Infect Dis J 1988;7: 388-93.
19. Vesikari T, Isolauri E, D'Hondt E, Delem A, Andre FE, Zissis G. Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine. Lancet 1984; 1:977-81.
20. Vesikari T, Isolauri E, Delem A, D’Hondt E, Andre FE, Beards GM, et al. Clinical efficacy of the RIT 4237 live attenuated bovine rotavirus vaccine in infants vaccinated before a rotavirus epidemic. J Pediatr 1985;107:189-94.
21. Wilde J, Yolken R, Willoughby R, Eiden J. Improved detection of rotavirus shedding by polymerase chain reaction. Lancet 1991;337:323-6.
22. Vesikari T, Varis T, Green K, Flores J, Kapikian AZ. Immu- nogenicity and safety of rhesus-human rotavirus reassortant vaccines with serotype 1 or 2 VP7 specificity. Vaccine 1991;9: 334-9.
23. Vesikari T, Kapikian AZ, Delem A, Zissis G. A comparative trial of rhesus monkey (RRV-1) and bovine (RIT 4237) oral rotavirus vaccines in young children. J Infect Dis 1986;153: 832-9.